Julie Rathbun

Investor Relations Contact en ATHIRA PHARMA, INC. .

Health Technology

Consumer Services

Perfil

Julie Rathbun is the founder and president of Rathbun Communications, Inc. founded in 2004.
She is currently the Head of Public and Investor Relations at Athira Pharma, Inc. Ms. Rathbun has previously worked as the Head of Investor Relations at Sarepta Therapeutics, Inc., Media Relations Contact at Immune Design Corp., and Media Contact at Neoleukin Therapeutics, Inc. Ms. Rathbun has an undergraduate degree from Western Washington University.

Cargos activos de Julie Rathbun

Empresas	Cargo	Inicio
ATHIRA PHARMA, INC.	Investor Relations Contact	-
Rathbun Communications, Inc.	Founder	01/01/2004

Todos los cargos activos de Julie Rathbun

Antiguos cargos conocidos de Julie Rathbun.

Empresas	Cargo	Fin
IMMUNE DESIGN CORP	Public Communications Contact	02/04/2019
NEUROGENE INC.	Public Communications Contact	-
SAREPTA THERAPEUTICS, INC.	Public Communications Contact	-

Ver el detalle de la experiencia de Julie Rathbun.

Formación de Julie Rathbun.

Western Washington University

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Julie Rathbun.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
SAREPTA THERAPEUTICS, INC.	Health Technology
ATHIRA PHARMA, INC.	Health Technology

Empresas privadas	3
Immune Design Corp. Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ.	Health Technology
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.	Health Technology
Rathbun Communications, Inc.

Ver las conexiones de la empresa